Umbrella Review: Cannabinoids Have Moderate Evidence Only for Chemo Nausea and Ulcerative Colitis QoL | Research

The takeaway

An overview of 68 systematic reviews covering 37 health conditions found no high-certainty evidence for cannabinoids in any condition. Moderate evidence supported benefit only for chemotherapy nausea and quality of life in ulcerative colitis.

Clinicians prescribing medical cannabis; guideline developers; patients seeking evidence-based cannabis information.

68 systematic reviews, 37 conditions: no high-certainty evidence for any

What the researchers found

Evidence certainty was not high for any cannabinoid outcome. Moderate evidence found: CBD may improve quality of life in ulcerative colitis but increases adverse events; cannabinoids appear to have no clinically important benefit for chronic non-cancer pain, MS spasticity pain, or acute postoperative pain; cannabinoids appear to reduce chemotherapy-related nausea and vomiting.

Why it matters

This is the most comprehensive overview of cannabis therapeutic evidence to date. By synthesizing 68 systematic reviews, it provides a definitive snapshot of where the evidence is strong, moderate, or insufficient, helping clinicians and patients make informed decisions.

The numbers in context

68 systematic reviews included. 37 health conditions addressed. 8 reviews rated high quality. No high-certainty evidence for any outcome. Moderate evidence for chemotherapy nausea benefit and no benefit for chronic non-cancer pain. For all other outcomes, evidence was low or very low.

How the study worked

Overview of systematic reviews (umbrella review). Identified 68 systematic reviews of randomized trials addressing 37 health conditions. Methodological quality assessed with AMSTAR-2 (8 rated high quality). Evidence certainty graded using GRADE framework.

What this study cannot tell us

Umbrella reviews depend on the quality of underlying systematic reviews. Rapidly evolving cannabis research means some newer studies may not be captured. The GRADE ratings are conservative and may underrate conditions where practical clinical experience suggests benefit.

How to read the evidence

Strong: comprehensive umbrella review with AMSTAR-2 quality assessment and GRADE evidence ratings.

When this study was published

Published in 2022.

The bigger picture

Despite thousands of studies, the evidence for most therapeutic cannabis applications remains weak. This overview highlights the gap between public enthusiasm and scientific evidence, and should guide research priorities toward conditions where preliminary signals exist.

Questions still open

Why does the evidence remain so weak despite decades of cannabis research? Would standardized cannabis products and better trial designs improve evidence quality? Which conditions should be prioritized for new rigorous trials?

Common questions

What conditions does cannabis actually help with?

Based on the highest available evidence, cannabinoids appear beneficial for reducing chemotherapy-related nausea and vomiting (moderate evidence). For chronic pain, multiple sclerosis spasticity, and most other conditions, the evidence is either insufficient or shows no clinically meaningful benefit.

Why is the evidence so weak for something millions of people use?

Cannabis research faces unique challenges: legal restrictions limit clinical trials, product inconsistency makes comparisons difficult, and many studies are small or poorly designed. The gap between patient experience and trial evidence remains wide.

Read the original research

Efficacy and safety of therapeutic use of cannabis derivatives and their synthetic analogs: Overview of systematic reviews.

Phytotherapy research : PTR, 36(1), 5-21

View on PubMed ↗Publisher’s paper ↗

Citation

Riera, Rachel; Pacheco, Rafael Leite; Bagattini, Ângela Maria; Martimbianco, Ana Luiza Cabrera. (2022). Efficacy and safety of therapeutic use of cannabis derivatives and their synthetic analogs: Overview of systematic reviews.. Phytotherapy research : PTR, 36(1), 5-21. https://doi.org/10.1002/ptr.7263